98%
921
2 minutes
20
The opportunistic pathogen, Acanthamoeba castellanii is the causative agent for the sight threatening infection Acanthamoeba keratitis (AK). It is commonly associated with contact lens wearers, and prevalence is increasing at an alarming rate due to an inadequate preventive strategy to protect the lens from this protist. This problem is compounded by the lack of an effective acanthamoebocide, particularly with cysticidal activity in the contact lens solutions. We have used cytotoxicity assays and a variety of biophysical approaches to show that two molecules with tails made of alkyl carbon, alkylphosphocholines (APCs) and quaternary ammonium compounds (QACs) had significant chain-length dependent efficacy against A. castellanii trophozoites, the latter producing death via permeabilization, and DNA complexing. QACs were more effective than APCs and had activity against cysts. Conversely, the QAC with 12 alkyl carbon chain, was non toxic, its presence increased A. castellanii trophozoites biomass and delayed encystation by 96 h. Interestingly, it was unable to induce excystation and increased trophozoite sensitivity to APC16. These results present a mono- and multi-inhibitor management strategy effective against trophozoites and cysts that may be useful for formulating into contact lense cleaning solutions and reducing AK incidence.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156471 | PMC |
http://dx.doi.org/10.1038/s41598-020-62934-8 | DOI Listing |
J Investig Allergol Clin Immunol
September 2025
Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Background And Objectives: Pollen-food allergy syndrome (PFAS) is a frequent comorbidity in individuals with hay fever. Identifying risk factors and allergen clusters can aid targeted interventions and management strategies. Objective: This study characterizes PFAS in patients with hay fever and identifies associated risk factors using the mobile health platform, AllerSearch.
View Article and Find Full Text PDFJ Biomed Opt
September 2025
Leibniz University Hannover, Hannover Centre for Optical Technologies, Hannover, Germany.
Significance: Melanoma's rising incidence demands automatable high-throughput approaches for early detection such as total body scanners, integrated with computer-aided diagnosis. High-quality input data is necessary to improve diagnostic accuracy and reliability.
Aim: This work aims to develop a high-resolution optical skin imaging module and the software for acquiring and processing raw image data into high-resolution dermoscopic images using a focus stacking approach.
Jpn J Ophthalmol
September 2025
Department of Ophthalmology, Osaka University Graduate School of Medicine, Room E7, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Abtract: PURPOSE: To evaluate the correlation between corneal backscatter and visual function in patients with Fuchs endothelial corneal dystrophy (FECD).
Study Design: Prospective case series.
Methods: This study included 53 eyes from 38 patients with FECD.
J Refract Surg
September 2025
Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Purpose: To report a case of acute and transient accommodative insufficiency after laser in situ keratomileusis (LASIK) due to coronavirus disease 2019 (COVID-19).
Methods: Case report and literature review.
Results: A 36-year-old man complained of acute blurred near vision 7 days after uneventful bilateral hyperopic LASIK, concurrent with the onset of COVID-19 infection.
Cornea
September 2025
Department of Ophthalmology, University of California Los Angeles, Los Angeles, CA.
Purpose: To evaluate visual outcomes after bacterial keratitis (BK) and identify predictive factors for poor prognosis at a tertiary referral center in Southern California.
Methods: This is a cross-sectional retrospective review of patients' medical records with culture-positive BK at University of California Los Angeles from January 1, 2014, to December 31, 2019. Main outcome measure was change in best-corrected visual acuity (BCVA) at 12 weeks posttreatment.